{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 505966, "items": [{"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T00:15:38Z", "timestamp": 1574295338777}, "reference-count": 38, "publisher": "Springer Science and Business Media LLC", "issue": "4", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2006, 8, 1]], "date-time": "2006-08-01T00:00:00Z", "timestamp": 1154390400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Curr Oncol Rep"], "published-print": {"date-parts": [[2006, 8]]}, "DOI": "10.1007/s11912-006-0030-8", "type": "journal-article", "created": {"date-parts": [[2007, 5, 25]], "date-time": "2007-05-25T17:19:59Z", "timestamp": 1180113599000}, "page": "258-264", "source": "Crossref", "is-referenced-by-count": 10, "title": ["Second-line treatment of small-cell lung cancer"], "prefix": "10.1007", "volume": "8", "author": [{"given": "Cecilia", "family": "MacCallum", "sequence": "first", "affiliation": []}, {"given": "Heidi H.", "family": "Gillenwater", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "30_CR1", "doi-asserted-by": "crossref", "first-page": "10", "DOI": "10.3322/canjclin.55.1.10", "volume": "55", "author": "A Jemal", "year": "2005", "unstructured": "Jemal A, Murray T, Ward E, et al.: Cancer statistics 2005. CA Cancer J Clin 2005, 55:10\u201330.", "journal-title": "CA Cancer J Clin"}, {"key": "30_CR2", "doi-asserted-by": "crossref", "first-page": "136", "DOI": "10.1097/00001622-200403000-00009", "volume": "16", "author": "K Chrystal", "year": "2004", "unstructured": "Chrystal K, Cheong K, Harper P: Chemotherapy of small cell lung cancer: state of the art. Current Opin Oncol 2004, 16:136\u2013140.", "journal-title": "Current Opin Oncol"}, {"key": "30_CR3", "doi-asserted-by": "crossref", "first-page": "1720", "DOI": "10.1016/0959-8049(93)90112-S", "volume": "29A", "author": "J Kassem", "year": "1993", "unstructured": "Kassem J, Karnicka-Mlodkowska H, van PottelsbergheC, van GlabbekeM: Phase II study of vinorelbine in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer 1993, 29A:1720.", "journal-title": "Eur J Cancer"}, {"issue": "Suppl 4", "key": "30_CR4", "doi-asserted-by": "crossref", "first-page": "S37", "DOI": "10.1016/S0169-5002(03)90525-3", "volume": "41", "author": "N Thatcher", "year": "2003", "unstructured": "Thatcher N, Eckardt J, Green M: Options for first and second line therapy in small cell lung cancer: a workshop discussion. Lung Cancer 2003, 41(Suppl 4):S37-S41.", "journal-title": "Lung Cancer"}, {"key": "30_CR5", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1016/S0169-5002(03)00039-4", "volume": "40", "author": "C Lima", "year": "2003", "unstructured": "Lima C, Chiappori A: Treatment of relapsed small cell lung cancer: a focus on the evolving role of topotecan. Lung Cancer 2003, 40:229\u2013236.", "journal-title": "Lung Cancer"}, {"key": "30_CR6", "doi-asserted-by": "crossref", "first-page": "2090", "DOI": "10.1200/JCO.1997.15.5.2090", "volume": "15", "author": "A Ardizzoni", "year": "1997", "unstructured": "Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in second-line treatment of small cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 1997, 15:2090\u20132096.", "journal-title": "J Clin Oncol"}, {"issue": "Suppl 5", "key": "30_CR7", "first-page": "107 (abstract 5", "volume": "7", "author": "J Eckardt", "year": "1996", "unstructured": "Eckardt J, Gralla R, Palmer M, et al.: Topotecan as second line therapy in patients with small cell lung cancer: a phase II study. Ann Oncol 1996, 7(Suppl 5):107 (abstract 513).", "journal-title": "Ann Oncol"}, {"issue": "Suppl 10", "key": "30_CR8", "first-page": "35 (abstract 12", "volume": "18", "author": "A Depierre", "year": "1997", "unstructured": "Depierre A, von Pawel J, Hans K, et al.: Evaluation of topotecan in relapsed small cell lung cancer. A multicenter phase II study. Lung Cancer 1997, 18(Suppl 10):35 (abstract 126).", "journal-title": "Lung Cancer"}, {"issue": "Suppl 8", "key": "30_CR9", "doi-asserted-by": "crossref", "first-page": "S229", "DOI": "10.1016/S0959-8049(97)85818-2", "volume": "33", "author": "J Pawel von", "year": "1997", "unstructured": "von PawelJ, Depierre A, Hans K, et al.: Topotecan in small cell lung cancer after failure of first line therapy: multicenter phase II study. Eur J Cancer 1997, 33(Suppl 8):S229.", "journal-title": "Eur J Cancer"}, {"key": "30_CR10", "doi-asserted-by": "crossref", "first-page": "658", "DOI": "10.1200/JCO.1999.17.2.658", "volume": "17", "author": "J Pawel von", "year": "1999", "unstructured": "von PawelJ, Schiller J, Shepherd F, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658\u2013667. This phase III trial led to FDA approval of topotecan as second-line therapy for SCLC.", "journal-title": "J Clin Oncol"}, {"key": "30_CR11", "first-page": "452a", "volume": "16", "author": "J Eckhardt", "year": "1997", "unstructured": "Eckhardt J, Depierre A, Ardizzoni A, et al.: Pooled analysis of topotecan in the second-line treatment of patients with sensitive small cell lung cancer [abstract]. Proc ASCO 1997, 16:452a.", "journal-title": "Proc ASCO"}, {"key": "30_CR12", "doi-asserted-by": "crossref", "first-page": "686", "DOI": "10.1634/theoncologist.10-9-686", "volume": "10", "author": "D Armstrong", "year": "2005", "unstructured": "Armstrong D, Spriggs D, Levin J, et al.: Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 2005, 10:686\u2013694.", "journal-title": "Oncologist"}, {"issue": "Suppl 1", "key": "30_CR13", "doi-asserted-by": "crossref", "first-page": "42", "DOI": "10.1016/S0169-5002(00)80136-1", "volume": "29", "author": "R Koschel", "year": "2000", "unstructured": "Koschel R, Huber R, Gatzemeirer U, et al.: Topotecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy. Lung Cancer 2000, 29(Suppl 1):42.", "journal-title": "Lung Cancer"}, {"key": "30_CR14", "doi-asserted-by": "crossref", "first-page": "173", "DOI": "10.1634/theoncologist.9-2-173", "volume": "9", "author": "J Treat", "year": "2004", "unstructured": "Treat J, Chao H, Lane S, Levin J. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004, 9:173\u2013181.", "journal-title": "Oncologist"}, {"issue": "14S", "key": "30_CR15", "doi-asserted-by": "crossref", "first-page": "7208", "DOI": "10.1200/jco.2004.22.14_suppl.7208", "volume": "22", "author": "J Levin", "year": "2004", "unstructured": "Levin J, Lilenbaum G, Masters A, et al.: Association of topotecan with improved performance status in relapsed small cell lung cancer patients with poor performance status at baseline [abstract]. J Clin Oncol Proc ASCO 2004, 22(14S):7208. This reference gives justification for treatment of patients with poor performance status with relapsed SCLC.", "journal-title": "J Clin Oncol Proc ASCO"}, {"key": "30_CR16", "first-page": "247", "volume": "43", "author": "A Bence", "year": "2002", "unstructured": "Bence A, Mattingly C, Desimone P, et al.: Evaluation of topotecan cytotoxicity and topoisomerase I levels in non-small cell lung cancer cells [abstract]. Proc Am Assoc Cancer Res 2002, 43:247.", "journal-title": "Proc Am Assoc Cancer Res"}, {"issue": "Suppl 6", "key": "30_CR17", "doi-asserted-by": "crossref", "first-page": "25", "DOI": "10.1634/theoncologist.9-90006-25", "volume": "9", "author": "J Eckardt", "year": "2004", "unstructured": "Eckardt J: Emerging role of weekly topotecan in recurrent small cell lung cancer. Oncologist 2004, 9(Suppl 6):25\u201332.", "journal-title": "Oncologist"}, {"issue": "Suppl 2", "key": "30_CR18", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1016/S0169-5002(03)92543-8", "volume": "41", "author": "F Greco", "year": "2003", "unstructured": "Greco F, Burris H, Yardley D, et al.: Phase II trial of weekly topotecan in the second line treatment of small cell lung cancer. Lung Cancer 2003, 41(Suppl 2):237.", "journal-title": "Lung Cancer"}, {"key": "30_CR19", "doi-asserted-by": "crossref", "first-page": "1743", "DOI": "10.1200/JCO.2001.19.6.1743", "volume": "19", "author": "J Pawel von", "year": "2001", "unstructured": "von PawelJ, Ulrich G, Jen-Louis P, et al.: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive SCLC. J Clin Oncol 2001, 19:1743\u20131749. This reported study demonstrates similar efficacy of oral versus intravenous topotecan.", "journal-title": "J Clin Oncol"}, {"key": "30_CR20", "first-page": "619 (abstract 2", "volume": "22", "author": "J Eckardt", "year": "2003", "unstructured": "Eckardt J, von PawelJ, Hainsworth D, et al.: Single agent oral topotecan (PO) versus intravenous topotecan (IV) in patients (pts) with chemo-sensitive small cell lung cancer (SCLC). An international phase III study [abstract]. Proc ASCO 2003, 22:619 (abstract 2488).", "journal-title": "Proc ASCO"}, {"key": "30_CR21", "first-page": "143", "volume": "9", "author": "A Ardizzoni", "year": "2003", "unstructured": "Ardizzoni A, Manegold C, Debruyne C, et al.: European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 2003, 9:143\u2013150.", "journal-title": "Clin Cancer Res"}, {"key": "30_CR22", "doi-asserted-by": "crossref", "first-page": "796", "DOI": "10.1007/s00280-005-0085-5", "volume": "57", "author": "G Stathopoulos", "year": "2006", "unstructured": "Stathopoulos G, Christodoulou C, Stathopoulos J, et al.: Second-line chemotherapy in small cell lung cancer n a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer Chemother Pharmacol 2006, 57:796\u2013800.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "30_CR23", "first-page": "686 (abstract 2", "volume": "22", "author": "C Jordan", "year": "2003", "unstructured": "Jordan C, Freiss G, Page R: Topotecan and vincristine as second line combination treatment of small cell lung cancer (SCLC) after failed first line therapy with carboplatin and etoposide [abstract]. Proc ASCO 2003, 22:686 (abstract 2757).", "journal-title": "Proc ASCO"}, {"key": "30_CR24", "first-page": "450A", "volume": "16", "author": "T Chavalier Le", "year": "1997", "unstructured": "Le Chavalier T, Ibrahim N, Chomy P: A phase II study of irinotecan in patients with small cell lung cancer progressing after response to first-line chemotherapy [abstract]. Proc ASCO 1997, 16:450A.", "journal-title": "Proc ASCO"}, {"key": "30_CR25", "first-page": "451A", "volume": "17", "author": "R Vore De", "year": "1998", "unstructured": "De Vore R, Blanke C, Denham J, et al.: Phase II study of irinotecan in patients with previously treated small cell lung cancer [abstract]. Proc ASCO 1998, 17:451A.", "journal-title": "Proc ASCO"}, {"key": "30_CR26", "doi-asserted-by": "crossref", "first-page": "3329", "DOI": "10.1200/JCO.1998.16.10.3329", "volume": "16", "author": "N Masuda", "year": "1998", "unstructured": "Masuda N, Negoro S, Takifuji N, et al.: Combination of irinotecan and etoposide for treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 1998, 16:3329\u20133334.", "journal-title": "J Clin Oncol"}, {"key": "30_CR27", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1038/bjc.1998.54", "volume": "77", "author": "E Smit", "year": "1998", "unstructured": "Smit E, Fokkema E, Biesma B, et al.: A phase II study of paclitaxel in heavily pretreated patients with small cell lung cancer. Br J Cancer 1998, 77:347\u2013351.", "journal-title": "Br J Cancer"}, {"key": "30_CR28", "doi-asserted-by": "crossref", "first-page": "193", "DOI": "10.1023/A:1008322932251", "volume": "12", "author": "S Kakolyris", "year": "2001", "unstructured": "Kakolyris S, Mavroudis D, Tsavaris N, et al.: Paclitaxel in combination with carboplatin as salvage treatment in refractory small cell lung cancer: a multicenter phase II study. Ann Oncol 2001, 12:193\u2013197.", "journal-title": "Ann Oncol"}, {"key": "30_CR29", "first-page": "1", "volume": "6", "author": "V Dongiovanni", "year": "2005", "unstructured": "Dongiovanni V, Buffoni L, Berruti A, et al.: Second line chemotherapy with weekly paclitaxel and gemcitabine in patients with small cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 2005, 6:1\u20137.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "30_CR30", "doi-asserted-by": "crossref", "first-page": "1550", "DOI": "10.1200/JCO.2003.09.130", "volume": "21", "author": "G Masters", "year": "2003", "unstructured": "Masters G, Declerck L, Blanke C, et al.: Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol 2003, 21:1550\u20131555.", "journal-title": "J Clin Oncol"}, {"key": "30_CR31", "first-page": "370", "volume": "56", "author": "G Krystal", "year": "1996", "unstructured": "Krystal G, Hines S, Organ C: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56:370\u2013376.", "journal-title": "Cancer Res"}, {"key": "30_CR32", "doi-asserted-by": "crossref", "first-page": "3521", "DOI": "10.1038/sj.onc.1203698", "volume": "19", "author": "W Wang", "year": "2000", "unstructured": "Wang W, Healy M, Sattler M, et al.: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000, 19:3521\u20133528.", "journal-title": "Oncogene"}, {"key": "30_CR33", "doi-asserted-by": "crossref", "first-page": "37", "DOI": "10.1038/bjc.1993.7", "volume": "67", "author": "K Rygaard", "year": "1993", "unstructured": "Rygaard K, Nakamura T, Spang-Thomsen M: Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993, 67:37\u201346.", "journal-title": "Br J Cancer"}, {"key": "30_CR34", "first-page": "2416", "volume": "51", "author": "Y Sekido", "year": "1991", "unstructured": "Sekido Y, Obata Y, Ueda R, et al.: Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991, 51:2416\u20132419.", "journal-title": "Cancer Res"}, {"key": "30_CR35", "first-page": "2291", "volume": "6", "author": "K Hibi", "year": "1991", "unstructured": "Hibi K, Obata Y, Ueda R, et al.: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991, 6:2291\u20132296.", "journal-title": "Oncogene"}, {"key": "30_CR36", "first-page": "5880", "volume": "9", "author": "B Johnson", "year": "2003", "unstructured": "Johnson B, Fischer T, Fischer B, et al.: Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9:5880\u20135887.", "journal-title": "Clin Cancer Res"}, {"key": "30_CR37", "doi-asserted-by": "crossref", "first-page": "1811", "DOI": "10.1093/annonc/mdi365", "volume": "16", "author": "G Dy", "year": "2005", "unstructured": "Dy G, Miller A, Mandrekar S, et al.: A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005, 16:1811\u20131816.", "journal-title": "Ann Oncol"}, {"key": "30_CR38", "first-page": "7047", "volume": "24", "author": "J Johl", "year": "2005", "unstructured": "Johl J, Chansky K, Lara P, et al.: The proteasome inhibitor PS-341(Bortezomib) in platinum (plat)-treated extensive-stage small cell lung cancer (E-SCLC): A SWOG (0327) phase II trial [abstract]. Proc ASCO 2005, 24:7047.", "journal-title": "Proc ASCO"}], "container-title": ["Current Oncology Reports"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s11912-006-0030-8.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s11912-006-0030-8/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s11912-006-0030-8", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 2]], "date-time": "2019-06-02T00:31:29Z", "timestamp": 1559435489000}, "score": 43.66736, "issued": {"date-parts": [[2006, 8]]}, "references-count": 38, "journal-issue": {"published-print": {"date-parts": [[2006, 8]]}, "issue": "4"}, "alternative-id": ["30"], "URL": "http://dx.doi.org/10.1007/s11912-006-0030-8", "relation": {"cites": []}, "ISSN": ["1523-3790", "1534-6269"], "issn-type": [{"value": "1523-3790", "type": "print"}, {"value": "1534-6269", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T22:13:09Z", "timestamp": 1574115189679}, "reference-count": 42, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1999, 8, 1]], "date-time": "1999-08-01T00:00:00Z", "timestamp": 933465600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Treatment Reviews"], "published-print": {"date-parts": [[1999, 8]]}, "DOI": "10.1053/ctrv.1999.0125", "type": "journal-article", "created": {"date-parts": [[2002, 7, 26]], "date-time": "2002-07-26T11:25:59Z", "timestamp": 1027682759000}, "page": "199-206", "source": "Crossref", "is-referenced-by-count": 36, "title": ["Second-line chemotherapy and its evaluation in small cell lung cancer"], "prefix": "10.1053", "volume": "25", "author": [{"given": "C.", "family": "Huisman", "sequence": "first", "affiliation": []}, {"given": "P.E.", "family": "Postmus", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Giaccone", "sequence": "additional", "affiliation": []}, {"given": "E.F.", "family": "Smit", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Cancer Treatment Reviews"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0305737299901251?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0305737299901251?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 11]], "date-time": "2019-04-11T21:27:32Z", "timestamp": 1555018052000}, "score": 37.705143, "issued": {"date-parts": [[1999, 8]]}, "references-count": 42, "journal-issue": {"published-print": {"date-parts": [[1999, 8]]}, "issue": "4"}, "alternative-id": ["S0305737299901251"], "URL": "http://dx.doi.org/10.1053/ctrv.1999.0125", "ISSN": ["0305-7372"], "issn-type": [{"value": "0305-7372", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T01:36:56Z", "timestamp": 1575250616520}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2018, 1, 1]], "date-time": "2018-01-01T00:00:00Z", "timestamp": 1514764800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2018, 1]]}, "DOI": "10.1016/s0169-5002(18)30101-6", "type": "journal-article", "created": {"date-parts": [[2018, 2, 21]], "date-time": "2018-02-21T19:16:23Z", "timestamp": 1519240583000}, "page": "S31", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The use of second or third line nivolumab in advanced non-small cell lung cancer: a west of Scotland experience"], "prefix": "10.1016", "volume": "115", "author": [{"given": "C.", "family": "Ali", "sequence": "first", "affiliation": []}, {"given": "K.", "family": "Yahya", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500218301016?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500218301016?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 8, 23]], "date-time": "2018-08-23T22:57:30Z", "timestamp": 1535065050000}, "score": 36.455574, "issued": {"date-parts": [[2018, 1]]}, "references-count": 0, "alternative-id": ["S0169500218301016"], "URL": "http://dx.doi.org/10.1016/s0169-5002(18)30101-6", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T16:59:52Z", "timestamp": 1575305992783}, "reference-count": 55, "publisher": "Elsevier BV", "issue": "2", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2001, 11, 1]], "date-time": "2001-11-01T00:00:00Z", "timestamp": 1004572800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lung Cancer"], "published-print": {"date-parts": [[2001, 11]]}, "DOI": "10.3816/clc.2001.n.022", "type": "journal-article", "created": {"date-parts": [[2008, 9, 11]], "date-time": "2008-09-11T01:11:51Z", "timestamp": 1221095511000}, "page": "118-124", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Second-Line Chemotherapy for Small-Cell Lung Cancer: A Review"], "prefix": "10.3816", "volume": "3", "author": [{"given": "Christian P.", "family": "Schultheis", "sequence": "first", "affiliation": []}, {"given": "Mohammed A.", "family": "Raheem", "sequence": "additional", "affiliation": []}, {"given": "Michael C.", "family": "Perry", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S152573041170763X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S152573041170763X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 5, 13]], "date-time": "2019-05-13T23:05:07Z", "timestamp": 1557788707000}, "score": 35.47332, "issued": {"date-parts": [[2001, 11]]}, "references-count": 55, "journal-issue": {"published-print": {"date-parts": [[2001, 11]]}, "issue": "2"}, "alternative-id": ["S152573041170763X"], "URL": "http://dx.doi.org/10.3816/clc.2001.n.022", "ISSN": ["1525-7304"], "issn-type": [{"value": "1525-7304", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T18:49:44Z", "timestamp": 1574189384730}, "reference-count": 16, "publisher": "Elsevier BV", "issue": "4", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2006, 4, 1]], "date-time": "2006-04-01T00:00:00Z", "timestamp": 1143849600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Chest"], "published-print": {"date-parts": [[2006, 4]]}, "DOI": "10.1378/chest.129.4.840", "type": "journal-article", "created": {"date-parts": [[2006, 4, 11]], "date-time": "2006-04-11T20:50:54Z", "timestamp": 1144788654000}, "page": "840-842", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Second-Line Chemotherapy for Non-small Cell Lung Cancer"], "prefix": "10.1016", "volume": "129", "author": [{"given": "John C.", "family": "Ruckdeschel", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Chest"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0012369215387948?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0012369215387948?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 17]], "date-time": "2019-01-17T05:50:14Z", "timestamp": 1547704214000}, "score": 35.31513, "issued": {"date-parts": [[2006, 4]]}, "references-count": 16, "journal-issue": {"published-print": {"date-parts": [[2006, 4]]}, "issue": "4"}, "alternative-id": ["S0012369215387948"], "URL": "http://dx.doi.org/10.1378/chest.129.4.840", "ISSN": ["0012-3692"], "issn-type": [{"value": "0012-3692", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 25]], "date-time": "2019-11-25T20:22:31Z", "timestamp": 1574713351554}, "reference-count": 0, "publisher": "AME Publishing Company", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Transl. Lung Cancer Res."], "published-print": {"date-parts": [[2016, 10]]}, "DOI": "10.21037/tlcr.2016.10.01", "type": "journal-article", "created": {"date-parts": [[2016, 11, 1]], "date-time": "2016-11-01T03:18:30Z", "timestamp": 1477970310000}, "page": "538-542", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Pembrolizumab as first-line treatment for non-small cell lung cancer\u2014a game changer?"], "prefix": "10.21037", "volume": "5", "author": [{"given": "Wolfram C. M.", "family": "Dempke", "sequence": "first", "affiliation": []}, {"given": "Klaus", "family": "Fenchel", "sequence": "additional", "affiliation": []}], "member": "8611", "published-online": {"date-parts": [[2016, 10]]}, "container-title": ["Translational Lung Cancer Research"], "link": [{"URL": "http://tlcr.amegroups.com/article/download/9968/8661", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 11, 1]], "date-time": "2016-11-01T03:18:35Z", "timestamp": 1477970315000}, "score": 34.806023, "issued": {"date-parts": [[2016, 10]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2016, 10]]}, "published-print": {"date-parts": [[2016, 10]]}, "issue": "5"}, "URL": "http://dx.doi.org/10.21037/tlcr.2016.10.01", "ISSN": ["2218-6751", "2226-4477"], "issn-type": [{"value": "2218-6751", "type": "print"}, {"value": "2226-4477", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T19:31:27Z", "timestamp": 1574451087619}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 1, 1]], "date-time": "2012-01-01T00:00:00Z", "timestamp": 1325376000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2012, 1]]}, "DOI": "10.1016/s0169-5002(12)70174-5", "type": "journal-article", "created": {"date-parts": [[2012, 2, 8]], "date-time": "2012-02-08T19:44:29Z", "timestamp": 1328730269000}, "page": "S57", "source": "Crossref", "is-referenced-by-count": 0, "title": ["173 Follow-up after first line treatment for extensive stage small cell lung cancer \u2013 another postcode lottery?"], "prefix": "10.1016", "volume": "75", "author": [{"given": "C.", "family": "Moss", "sequence": "first", "affiliation": []}, {"given": "I.", "family": "Khan", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "Ngai", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Billingham", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Shah", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500212701745?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500212701745?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 11, 26]], "date-time": "2018-11-26T11:55:01Z", "timestamp": 1543233301000}, "score": 34.396294, "issued": {"date-parts": [[2012, 1]]}, "references-count": 0, "alternative-id": ["S0169500212701745"], "URL": "http://dx.doi.org/10.1016/s0169-5002(12)70174-5", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 27]], "date-time": "2019-11-27T05:23:30Z", "timestamp": 1574832210558}, "reference-count": 60, "publisher": "Springer Science and Business Media LLC", "issue": "14", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 8, 24]], "date-time": "2016-08-24T00:00:00Z", "timestamp": 1471996800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Drugs"], "published-print": {"date-parts": [[2016, 9]]}, "DOI": "10.1007/s40265-016-0628-6", "type": "journal-article", "created": {"date-parts": [[2016, 8, 24]], "date-time": "2016-08-24T16:18:09Z", "timestamp": 1472055489000}, "page": "1321-1336", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations"], "prefix": "10.1007", "volume": "76", "author": [{"given": "Paul C.", "family": "Barnfield", "sequence": "first", "affiliation": []}, {"given": "Peter M.", "family": "Ellis", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 8, 24]]}, "reference": [{"issue": "30", "key": "628_CR1", "doi-asserted-by": "crossref", "first-page": "3488", "DOI": "10.1200/JCO.2015.62.1342", "volume": "33", "author": "GA Masters", "year": "2015", "unstructured": "Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488\u2013515.", "journal-title": "J Clin Oncol"}, {"issue": "Suppl 3", "key": "628_CR2", "doi-asserted-by": "crossref", "first-page": "iii27", "DOI": "10.1093/annonc/mdu199", "volume": "25", "author": "M Reck", "year": "2014", "unstructured": "Reck M, Popat S, Reinmuth N, De Ruyssher D, Kerr K, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27\u201339.", "journal-title": "Ann Oncol."}, {"issue": "10", "key": "628_CR3", "doi-asserted-by": "crossref", "first-page": "2095", "DOI": "10.1200/JCO.2000.18.10.2095", "volume": "18", "author": "FA Shepherd", "year": "2000", "unstructured": "Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O\u2019Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095\u2013103.", "journal-title": "J Clin Oncol"}, {"issue": "9", "key": "628_CR4", "doi-asserted-by": "crossref", "first-page": "1589", "DOI": "10.1200/JCO.2004.08.163", "volume": "22", "author": "N Hanna", "year": "2004", "unstructured": "Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589\u201397.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "628_CR5", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa050753", "volume": "353", "author": "FA Shepherd", "year": "2005", "unstructured": "Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123\u201332.", "journal-title": "N Engl J Med"}, {"issue": "9652", "key": "628_CR6", "doi-asserted-by": "crossref", "first-page": "1809", "DOI": "10.1016/S0140-6736(08)61758-4", "volume": "372", "author": "ES Kim", "year": "2008", "unstructured": "Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809\u201318.", "journal-title": "Lancet"}, {"key": "628_CR7", "doi-asserted-by": "crossref", "first-page": "300", "DOI": "10.1016/S1470-2045(11)70385-0", "volume": "13", "author": "T Ciuleanu", "year": "2012", "unstructured": "Ciuleanu T, Stelmakh L, Cicena S, Miliauskas S, Grigorescu A, Hillenback C, Johannsdottir K, Klughammer B, Gonzales E. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300\u20138.", "journal-title": "Lancet Oncol."}, {"issue": "15", "key": "628_CR8", "doi-asserted-by": "crossref", "first-page": "2754", "DOI": "10.1002/cncr.28132", "volume": "119", "author": "A Karampeazis", "year": "2013", "unstructured": "Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013;119(15):2754\u201364.", "journal-title": "Cancer"}, {"issue": "10", "key": "628_CR9", "doi-asserted-by": "crossref", "first-page": "981", "DOI": "10.1016/S1470-2045(13)70310-3", "volume": "14", "author": "MC Garassino", "year": "2013", "unstructured": "Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14(10):981\u20138.", "journal-title": "Lancet Oncol."}, {"issue": "18", "key": "628_CR10", "doi-asserted-by": "crossref", "first-page": "1902", "DOI": "10.1200/JCO.2013.52.4694", "volume": "32", "author": "T Kawaguchi", "year": "2014", "unstructured": "Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: docetaxel and erlotinib lung cancer trial (DELTA). J Clin Oncol. 2014;32(18):1902\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "12", "key": "628_CR11", "doi-asserted-by": "crossref", "first-page": "2385", "DOI": "10.1093/annonc/mdu463", "volume": "25", "author": "Q Zhou", "year": "2014", "unstructured": "Zhou Q, Cheng Y, Yang JJ, Zhao MF, Zhang L, Zhang XC, et al. Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial. Ann Oncol. 2014;25(12):2385\u201391.", "journal-title": "Ann Oncol"}, {"key": "628_CR12", "doi-asserted-by": "crossref", "first-page": "1430", "DOI": "10.1001/jama.2014.3314", "volume": "311", "author": "J-K Lee", "year": "2014", "unstructured": "Lee J-K, Hahn S, Kim D-W, Su K, Keam B, Kim T, Lee S-H, Heo D. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor. JAMA. 2014;311:1430\u20137.", "journal-title": "JAMA"}, {"issue": "13", "key": "628_CR13", "doi-asserted-by": "crossref", "first-page": "2167", "DOI": "10.1200/JCO.2009.23.4146", "volume": "28", "author": "M Krzakowski", "year": "2010", "unstructured": "Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P, Von Pawel J, et al. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol. 2010;28(13):2167\u201373.", "journal-title": "J Clin Oncol"}, {"issue": "8", "key": "628_CR14", "doi-asserted-by": "crossref", "first-page": "216", "DOI": "10.1007/s12032-015-0660-5", "volume": "32", "author": "Z Liu", "year": "2015", "unstructured": "Liu Z, Wei Z, Hu Y, Gao F, Hao L, Fang P, et al. A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. Med Oncol. 2015;32(8):216.", "journal-title": "Med Oncol"}, {"key": "628_CR15", "doi-asserted-by": "crossref", "first-page": "2800", "DOI": "10.1200/JCO.2005.03.6491", "volume": "24", "author": "R Ramlau", "year": "2006", "unstructured": "Ramlau R, Gervais R, Krzakowski M, von Pawel J, Kaukel E, Abratt R, Dharan B, Grotzinger K, Ross G, Dane D, Shepherd F. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:2800\u20137.", "journal-title": "J Clin Oncol."}, {"issue": "10", "key": "628_CR16", "doi-asserted-by": "crossref", "first-page": "953", "DOI": "10.1016/S1470-2045(13)70355-3", "volume": "14", "author": "Y Shi", "year": "2013", "unstructured": "Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14(10):953\u201361.", "journal-title": "Lancet Oncol."}, {"issue": "27", "key": "628_CR17", "doi-asserted-by": "crossref", "first-page": "3337", "DOI": "10.1200/JCO.2011.40.9433", "volume": "30", "author": "SS Ramalingam", "year": "2012", "unstructured": "Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non\u2013small-cell lung cancer. J Clin Oncol. 2012;30(27):3337\u201344.", "journal-title": "J Clin Oncol."}, {"issue": "12", "key": "628_CR18", "doi-asserted-by": "crossref", "first-page": "1369", "DOI": "10.1016/S1470-2045(14)70452-8", "volume": "15", "author": "SS Ramalingam", "year": "2014", "unstructured": "Ramalingam SS, Janne PA, Mok T, O\u2019Byrne K, Boyer MJ, Von Pawel J, et al. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(12):1369\u201378.", "journal-title": "Lancet Oncol."}, {"issue": "8", "key": "628_CR19", "doi-asserted-by": "crossref", "first-page": "1059", "DOI": "10.1200/JCO.2010.28.5981", "volume": "29", "author": "RB Natale", "year": "2011", "unstructured": "Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(8):1059\u201366.", "journal-title": "J Clin Oncol"}, {"issue": "8", "key": "628_CR20", "doi-asserted-by": "crossref", "first-page": "897", "DOI": "10.1016/S1470-2045(15)00006-6", "volume": "16", "author": "J-C Soria", "year": "2015", "unstructured": "Soria J-C, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897\u2013907.", "journal-title": "Lancet Oncol."}, {"issue": "5", "key": "628_CR21", "doi-asserted-by": "crossref", "first-page": "894", "DOI": "10.1093/annonc/mdv072", "volume": "26", "author": "GR Blumenschein Jr", "year": "2015", "unstructured": "Blumenschein GR Jr, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)+. Ann Oncol. 2015;26(5):894\u2013901.", "journal-title": "Ann Oncol"}, {"issue": "36", "key": "628_CR22", "doi-asserted-by": "crossref", "first-page": "4501", "DOI": "10.1200/JCO.2012.43.6758", "volume": "30", "author": "A Ardizzoni", "year": "2012", "unstructured": "Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, et al. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol. 2012;30(36):4501\u20137.", "journal-title": "J Clin Oncol"}, {"key": "628_CR23", "doi-asserted-by": "crossref", "first-page": "1836", "DOI": "10.1200/JCO.2008.17.5844", "volume": "27", "author": "M Maio Di", "year": "2009", "unstructured": "Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters F, Gebbia V, Smit E, Morabito A, Gallow C, Perrone F, Gridelli C. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009;27:1836\u201343.", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "628_CR24", "doi-asserted-by": "crossref", "first-page": "2542", "DOI": "10.1056/NEJMoa061884", "volume": "355", "author": "A Sandler", "year": "2006", "unstructured": "Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542\u201350.", "journal-title": "N Engl J Med."}, {"key": "628_CR25", "doi-asserted-by": "crossref", "first-page": "4744", "DOI": "10.1200/JCO.2007.12.3026", "volume": "25", "author": "RS Herbst", "year": "2007", "unstructured": "Herbst RS, Vincent J, O\u2019Neill LF, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol. 2007;25:4744\u201350.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "628_CR26", "doi-asserted-by": "crossref", "first-page": "1050", "DOI": "10.1002/cncr.29893", "volume": "122", "author": "M Takeda", "year": "2016", "unstructured": "Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): an open-label, randomized, phase 2 trial. Cancer. 2016;122(7):1050\u20139.", "journal-title": "Cancer"}, {"issue": "9944", "key": "628_CR27", "doi-asserted-by": "crossref", "first-page": "665", "DOI": "10.1016/S0140-6736(14)60845-X", "volume": "384", "author": "EB Garon", "year": "2014", "unstructured": "Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665\u201373.", "journal-title": "Lancet"}, {"key": "628_CR28", "doi-asserted-by": "crossref", "first-page": "3640", "DOI": "10.1200/JCO.2012.42.6932", "volume": "30", "author": "R Ramlau", "year": "2012", "unstructured": "Ramlau R, Gorbunova V, Ciulenau T, Novello S, Ozguroglu M, Gokesel T, Baldotto C, Bennouna J, Shepherd F, Le-Guennec S, Rey A, Miller V, Thatcher N, Scagliotti G. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clinical Oncol. 2012;30:3640\u20137.", "journal-title": "J Clinical Oncol."}, {"issue": "2", "key": "628_CR29", "doi-asserted-by": "crossref", "first-page": "143", "DOI": "10.1016/S1470-2045(13)70586-2", "volume": "15", "author": "M Reck", "year": "2014", "unstructured": "Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143\u201355.", "journal-title": "Lancet Oncol."}, {"issue": "15 Suppl", "key": "628_CR30", "first-page": "8034", "volume": "31", "author": "NH Hanna", "year": "2013", "unstructured": "Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn M-J, Tiangco B, et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. ASCO Meet Abstr. 2013;31(15 Suppl):8034.", "journal-title": "ASCO Meet Abstr."}, {"issue": "8", "key": "628_CR31", "doi-asserted-by": "crossref", "first-page": "1067", "DOI": "10.1200/JCO.2010.29.5717", "volume": "29", "author": "RH Boer de", "year": "2011", "unstructured": "de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;29(8):1067\u201374.", "journal-title": "J Clin Oncol"}, {"issue": "7", "key": "628_CR32", "doi-asserted-by": "crossref", "first-page": "619", "DOI": "10.1016/S1470-2045(10)70132-7", "volume": "11", "author": "RS Herbst", "year": "2010", "unstructured": "Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010;11(7):619\u201326.", "journal-title": "Lancet Oncol."}, {"issue": "2", "key": "628_CR33", "doi-asserted-by": "crossref", "first-page": "214", "DOI": "10.1097/JTO.0000000000000071", "volume": "9", "author": "RS Heist", "year": "2014", "unstructured": "Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, et al. CALGB 30704 (Alliance): a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(2):214\u201321.", "journal-title": "J Thorac Oncol."}, {"issue": "6", "key": "628_CR34", "doi-asserted-by": "crossref", "first-page": "e0127306", "DOI": "10.1371/journal.pone.0127306", "volume": "10", "author": "J Sheng", "year": "2015", "unstructured": "Sheng J, Yang Y, Ma Y, Yang B, Zhang Y, Kang S, et al. The efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0127306.", "journal-title": "PLoS One"}, {"issue": "13", "key": "628_CR35", "doi-asserted-by": "crossref", "first-page": "1326", "DOI": "10.1016/S1470-2045(13)70473-X", "volume": "14", "author": "ES Kim", "year": "2013", "unstructured": "Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.[Erratum appears in Lancet Oncol. 2014 Jan; 15(1):e4]. Lancet Oncol. 2013;14(13):1326\u201336.", "journal-title": "Lancet Oncol."}, {"issue": "9", "key": "628_CR36", "doi-asserted-by": "crossref", "first-page": "1571", "DOI": "10.1016/j.ejca.2014.03.007", "volume": "50", "author": "C Dittrich", "year": "2014", "unstructured": "Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, et al. A randomised phase II study of pemetrexed versus pemetrexed\u00a0+\u00a0erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Eur J Cancer. 2014;50(9):1571\u201380.", "journal-title": "Eur J Cancer"}, {"issue": "11", "key": "628_CR37", "doi-asserted-by": "crossref", "first-page": "2860", "DOI": "10.1093/annonc/mdt341", "volume": "24", "author": "JG Aerts", "year": "2013", "unstructured": "Aerts JG, Codrington H, Lankheet NA, Burgers S, Biesma B, Dingemans AM, et al. A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study. Ann Oncol. 2013;24(11):2860\u20135.", "journal-title": "Ann Oncol"}, {"issue": "6", "key": "628_CR38", "doi-asserted-by": "crossref", "first-page": "457", "DOI": "10.1016/j.cllc.2015.05.010", "volume": "16", "author": "PM Ellis", "year": "2015", "unstructured": "Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, et al. A randomized, open-label phase II trial of volasertib as monotherapy and in combination with standard-dose pemetrexed compared with pemetrexed monotherapy in second-line treatment for non-small-cell lung cancer. Clin Lung Cancer. 2015;16(6):457\u201365.", "journal-title": "Clin Lung Cancer."}, {"issue": "3", "key": "628_CR39", "doi-asserted-by": "crossref", "first-page": "420", "DOI": "10.1016/j.lungcan.2009.07.011", "volume": "68", "author": "GV Scagliotti", "year": "2010", "unstructured": "Scagliotti GV, Germonpre P, Bosquee L, Vansteenkiste J, Gervais R, Planchard D, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer. 2010;68(3):420\u20136.", "journal-title": "Lung Cancer"}, {"issue": "4", "key": "628_CR40", "doi-asserted-by": "crossref", "first-page": "781", "DOI": "10.1097/JTO.0b013e31820a0ea6", "volume": "6", "author": "N Ready", "year": "2011", "unstructured": "Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, et al. Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. J Thorac Oncol. 2011;6(4):781\u20135.", "journal-title": "J Thorac Oncol."}, {"key": "628_CR41", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa050753", "volume": "353", "author": "F Shepherd", "year": "2005", "unstructured": "Shepherd F, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123\u201332.", "journal-title": "N Engl J Med"}, {"key": "628_CR42", "doi-asserted-by": "crossref", "first-page": "1846", "DOI": "10.1016/S0140-6736(11)60545-X", "volume": "377", "author": "R Herbst", "year": "2011", "unstructured": "Herbst R, Ansari R, Bustin F, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard fi rst-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377:1846\u201354.", "journal-title": "Lancet"}, {"issue": "9", "key": "628_CR43", "doi-asserted-by": "crossref", "first-page": "2382", "DOI": "10.1093/annonc/mdt212", "volume": "24", "author": "HJ Groen", "year": "2013", "unstructured": "Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol. 2013;24(9):2382\u20139.", "journal-title": "Ann Oncol"}, {"issue": "18", "key": "628_CR44", "doi-asserted-by": "crossref", "first-page": "2582", "DOI": "10.1200/JCO.2010.30.7678", "volume": "29", "author": "DR Spigel", "year": "2011", "unstructured": "Spigel DR, Burris HA 3rd, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2011;29(18):2582\u20139.", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "628_CR45", "doi-asserted-by": "crossref", "first-page": "3307", "DOI": "10.1200/JCO.2010.34.0570", "volume": "29", "author": "LV Sequist", "year": "2011", "unstructured": "Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 2011;29(24):3307\u201315.", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "628_CR46", "doi-asserted-by": "crossref", "first-page": "2667", "DOI": "10.1200/JCO.2014.60.7317", "volume": "33", "author": "G Scagliotti", "year": "2015", "unstructured": "Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(24):2667\u201374.", "journal-title": "J Clin Oncol"}, {"key": "628_CR47", "doi-asserted-by": "crossref", "first-page": "4106", "DOI": "10.1200/JCO.2012.47.4189", "volume": "31", "author": "D Spigel", "year": "2013", "unstructured": "Spigel D, Ervin T, Ramlau R, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4106\u201314.", "journal-title": "J Clin Oncol"}, {"key": "628_CR48", "first-page": "5s", "volume": "32", "author": "DR Spigel", "year": "2015", "unstructured": "Spigel DR, Edelman MJ, O\u2019Byrne K, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol. 2015;32:5s (supple;abstr 8000).", "journal-title": "J Clin Oncol."}, {"issue": "2", "key": "628_CR49", "doi-asserted-by": "crossref", "first-page": "409", "DOI": "10.1093/annonc/mdt536", "volume": "25", "author": "B Besse", "year": "2014", "unstructured": "Besse B, Leighl N, Bennouna J, Papadimitrakopoulou VA, Blais N, Traynor AM, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol. 2014;25(2):409\u201315.", "journal-title": "Ann Oncol"}, {"issue": "10", "key": "628_CR50", "doi-asserted-by": "crossref", "first-page": "1623", "DOI": "10.1097/JTO.0b013e3181ec1531", "volume": "5", "author": "K Price", "year": "2010", "unstructured": "Price K, Azzoii C, Krug L, et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(10):1623\u20139.", "journal-title": "J Thorac Oncol."}, {"issue": "10", "key": "628_CR51", "doi-asserted-by": "crossref", "first-page": "1574", "DOI": "10.1097/JTO.0b013e31826149ba", "volume": "7", "author": "HA Wakelee", "year": "2012", "unstructured": "Wakelee HA, Lee JW, Hanna NH, Traynor AM, Carbone DP, Schiller JH. A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. J Thorac Oncol. 2012;7(10):1574\u201382.", "journal-title": "J Thorac Oncol."}, {"issue": "12", "key": "628_CR52", "doi-asserted-by": "crossref", "first-page": "1745", "DOI": "10.1097/JTO.0000000000000693", "volume": "10", "author": "L Paz-Ares", "year": "2015", "unstructured": "Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, et al. Monotherapy administration of sorafenib in patients with non-small cell lung cancer (MISSION) Trial: a phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous non-small-cell lung cancer after 2 or 3 previous treatment regimens. J Thorac Oncol. 2015;10(12):1745\u201353.", "journal-title": "J Thorac Oncol."}, {"key": "628_CR53", "doi-asserted-by": "crossref", "first-page": "1114", "DOI": "10.1200/JCO.2011.36.1709", "volume": "30", "author": "J Lee", "year": "2012", "unstructured": "Lee J, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol. 2012;30:1114\u201321.", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "628_CR54", "doi-asserted-by": "crossref", "first-page": "528", "DOI": "10.1016/S1470-2045(12)70087-6", "volume": "13", "author": "VA Miller", "year": "2012", "unstructured": "Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528\u201338.", "journal-title": "Lancet Oncol."}, {"issue": "12", "key": "628_CR55", "doi-asserted-by": "crossref", "first-page": "1379", "DOI": "10.1016/S1470-2045(14)70472-3", "volume": "15", "author": "PM Ellis", "year": "2014", "unstructured": "Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014;15(12):1379\u201388.", "journal-title": "Lancet Oncol."}, {"issue": "2", "key": "628_CR56", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "volume": "373", "author": "J Brahmer", "year": "2015", "unstructured": "Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.", "journal-title": "N Engl J Med"}, {"issue": "17", "key": "628_CR57", "doi-asserted-by": "crossref", "first-page": "1627", "DOI": "10.1056/NEJMoa1507643", "volume": "373", "author": "H Borghaei", "year": "2015", "unstructured": "Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.", "journal-title": "N Engl J Med"}, {"issue": "10030", "key": "628_CR58", "doi-asserted-by": "crossref", "first-page": "1837", "DOI": "10.1016/S0140-6736(16)00587-0", "volume": "387", "author": "L Fehrenbacher", "year": "2016", "unstructured": "Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837\u201346.", "journal-title": "Lancet"}, {"issue": "17", "key": "628_CR59", "doi-asserted-by": "crossref", "first-page": "2070", "DOI": "10.1200/JCO.2011.39.2993", "volume": "30", "author": "GV Scagliotti", "year": "2012", "unstructured": "Scagliotti GV, Krzakowski M, Szczesna A, Strausz J, Makhson A, Reck M, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol. 2012;30(17):2070\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "10027", "key": "628_CR60", "doi-asserted-by": "crossref", "first-page": "1540", "DOI": "10.1016/S0140-6736(15)01281-7", "volume": "387", "author": "RS Herbst", "year": "2016", "unstructured": "Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.", "journal-title": "Lancet"}], "container-title": ["Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s40265-016-0628-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s40265-016-0628-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40265-016-0628-6", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 12]], "date-time": "2019-09-12T22:52:24Z", "timestamp": 1568328744000}, "score": 34.049915, "issued": {"date-parts": [[2016, 8, 24]]}, "references-count": 60, "journal-issue": {"published-print": {"date-parts": [[2016, 9]]}, "issue": "14"}, "alternative-id": ["628"], "URL": "http://dx.doi.org/10.1007/s40265-016-0628-6", "relation": {"cites": []}, "ISSN": ["0012-6667", "1179-1950"], "issn-type": [{"value": "0012-6667", "type": "print"}, {"value": "1179-1950", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 3]], "date-time": "2019-12-03T16:03:04Z", "timestamp": 1575388984099}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2019, 1, 1]], "date-time": "2019-01-01T00:00:00Z", "timestamp": 1546300800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2019, 1]]}, "DOI": "10.1016/s0169-5002(19)30146-1", "type": "journal-article", "created": {"date-parts": [[2019, 1, 25]], "date-time": "2019-01-25T08:13:58Z", "timestamp": 1548404038000}, "page": "S43", "source": "Crossref", "is-referenced-by-count": 0, "title": ["The experience of immunotherapy in lung cancer: an audit of immunotherapy use as second-line treatment for metastatic non-small cell lung cancer (NSCLC) in the South Tees region"], "prefix": "10.1016", "volume": "127", "author": [{"given": "T.", "family": "Hairudin", "sequence": "first", "affiliation": []}, {"given": "L.", "family": "Li", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Mansy", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Aynsley", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Kumar", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Masinghe", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Peedell", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500219301461?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500219301461?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 26]], "date-time": "2019-02-26T09:22:36Z", "timestamp": 1551172956000}, "score": 33.770466, "issued": {"date-parts": [[2019, 1]]}, "references-count": 0, "alternative-id": ["S0169500219301461"], "URL": "http://dx.doi.org/10.1016/s0169-5002(19)30146-1", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T19:19:24Z", "timestamp": 1574104764352}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1997, 8, 1]], "date-time": "1997-08-01T00:00:00Z", "timestamp": 870393600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[1997, 8]]}, "DOI": "10.1016/s0169-5002(97)83936-0", "type": "journal-article", "created": {"date-parts": [[2002, 7, 25]], "date-time": "2002-07-25T22:37:28Z", "timestamp": 1027636648000}, "page": "120", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Current treatment of advanced small cell lung cancer"], "prefix": "10.1016", "volume": "18", "author": [{"given": "Daniel C.", "family": "Ihde", "sequence": "first", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500297839360?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500297839360?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 4, 19]], "date-time": "2019-04-19T01:52:17Z", "timestamp": 1555638737000}, "score": 33.463463, "issued": {"date-parts": [[1997, 8]]}, "references-count": 0, "alternative-id": ["S0169500297839360"], "URL": "http://dx.doi.org/10.1016/s0169-5002(97)83936-0", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:16:05Z", "timestamp": 1575173765142}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 7, 1]], "date-time": "2005-07-01T00:00:00Z", "timestamp": 1120176000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2005, 7]]}, "DOI": "10.1016/s0169-5002(05)81081-5", "type": "journal-article", "created": {"date-parts": [[2005, 9, 7]], "date-time": "2005-09-07T19:17:09Z", "timestamp": 1126120629000}, "page": "S273", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P-588 Biweekly docetaxel and vinorelbine as second-line treatment in advanced (stage IIIB+ IV) non-small-cell lung cancer (NSCLC). A phase II study of the Galician Lung Cancer Group"], "prefix": "10.1016", "volume": "49", "author": [{"given": "S.", "family": "V\u00e1zquez", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Villanueva", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Amenedo", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Firvida", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "L\u00e1zaro", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Del R\u00edo", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Huidobro", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Mel", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Ramos", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Grande", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500205810815?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500205810815?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T14:28:01Z", "timestamp": 1548167281000}, "score": 33.172615, "issued": {"date-parts": [[2005, 7]]}, "references-count": 0, "alternative-id": ["S0169500205810815"], "URL": "http://dx.doi.org/10.1016/s0169-5002(05)81081-5", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:16:15Z", "timestamp": 1575173775919}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 7, 1]], "date-time": "2005-07-01T00:00:00Z", "timestamp": 1120176000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2005, 7]]}, "DOI": "10.1016/s0169-5002(05)80402-7", "type": "journal-article", "created": {"date-parts": [[2005, 9, 7]], "date-time": "2005-09-07T19:58:28Z", "timestamp": 1126123108000}, "page": "S86-S87", "source": "Crossref", "is-referenced-by-count": 0, "title": ["PD-069 Quality-of-Life (COL) assessment in two docetaxel dose-schedulesas second-line treatment of advanced non small cell lung cancer (NSCLC): Spanish Lung Cancer Group (SLCG) Phase III trial"], "prefix": "10.1016", "volume": "49", "author": [{"given": "C.", "family": "Camps", "sequence": "first", "affiliation": []}, {"given": "B.", "family": "Massuti", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Jim\u00e9nez", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Maestu", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Garcia", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Isla", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Gonz\u00e1lez-Larriba", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Almenar", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Carrato", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Rosell", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500205804027?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500205804027?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T14:22:30Z", "timestamp": 1548166950000}, "score": 33.172615, "issued": {"date-parts": [[2005, 7]]}, "references-count": 0, "alternative-id": ["S0169500205804027"], "URL": "http://dx.doi.org/10.1016/s0169-5002(05)80402-7", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T14:53:08Z", "timestamp": 1574434388359}, "reference-count": 0, "publisher": "Instituto de Salud Carlos III/BNCS/SciELO Espana", "issue": "5", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Oncolog\u00eda (Barc.)"], "DOI": "10.4321/s0378-48352006000500002", "type": "journal-article", "created": {"date-parts": [[2010, 6, 4]], "date-time": "2010-06-04T09:34:49Z", "timestamp": 1275644089000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["Phase II study: combination of carboplatin and paclitaxel as second-line treatment in metastatic non-small-cell lung cancer"], "prefix": "10.4321", "volume": "29", "author": [{"given": "R.", "family": "Espinosa", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "S\u00e1nchez", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Maximiano", "sequence": "additional", "affiliation": []}, {"given": "A.", "family": "Hurtado", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Espinosa", "sequence": "additional", "affiliation": []}, {"given": "P.", "family": "Espa\u00f1a", "sequence": "additional", "affiliation": []}], "member": "2868", "published-online": {"date-parts": [[2006, 5]]}, "container-title": ["Oncolog\u00eda (Barcelona)"], "language": "en", "deposited": {"date-parts": [[2010, 6, 4]], "date-time": "2010-06-04T09:34:50Z", "timestamp": 1275644090000}, "score": 33.130634, "issued": {"date-parts": [[2006, 5]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2006]]}, "issue": "5"}, "alternative-id": ["S0378-48352006000500002"], "URL": "http://dx.doi.org/10.4321/s0378-48352006000500002", "ISSN": ["0378-4835"], "issn-type": [{"value": "0378-4835", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T23:40:55Z", "timestamp": 1574120455370}, "reference-count": 0, "publisher": "Elsevier BV", "issue": "5-6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[1993, 2, 1]], "date-time": "1993-02-01T00:00:00Z", "timestamp": 728524800000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[1993, 2]]}, "DOI": "10.1016/0169-5002(93)90539-a", "type": "journal-article", "created": {"date-parts": [[2004, 4, 19]], "date-time": "2004-04-19T15:37:15Z", "timestamp": 1082389035000}, "page": "338", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Alternative splicing of neural-cell-adhesion molecule mRNA in human small-cell lung-cancer cell line H69"], "prefix": "10.1016", "volume": "8", "author": [{"given": "CEC", "family": "Moolenaarr", "sequence": "first", "affiliation": []}, {"given": "C", "family": "Pieneman", "sequence": "additional", "affiliation": []}, {"given": "FS", "family": "Walsh", "sequence": "additional", "affiliation": []}, {"given": "WJ", "family": "Mooi", "sequence": "additional", "affiliation": []}, {"given": "RJAM", "family": "Michalides", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:016950029390539A?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:016950029390539A?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 11]], "date-time": "2019-02-11T17:20:45Z", "timestamp": 1549905645000}, "score": 32.90242, "issued": {"date-parts": [[1993, 2]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1993, 2]]}, "issue": "5-6"}, "alternative-id": ["016950029390539A"], "URL": "http://dx.doi.org/10.1016/0169-5002(93)90539-a", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 18]], "date-time": "2019-11-18T20:44:26Z", "timestamp": 1574109866666}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2003, 8, 1]], "date-time": "2003-08-01T00:00:00Z", "timestamp": 1059696000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2003, 8]]}, "DOI": "10.1016/s0169-5002(03)91659-x", "type": "journal-article", "created": {"date-parts": [[2004, 1, 8]], "date-time": "2004-01-08T10:37:05Z", "timestamp": 1073558225000}, "page": "S4", "source": "Crossref", "is-referenced-by-count": 3, "title": ["O-1 A phase III trial comparing weekly and three weekly docetaxel in second line treatment of patients with advanced non small cell lung cancer (NSCLC)"], "prefix": "10.1016", "volume": "41", "author": [{"given": "Wolfgang", "family": "Schuette", "sequence": "first", "affiliation": []}, {"given": "Sylke", "family": "Nagel", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Lautenschlaeger", "sequence": "additional", "affiliation": []}, {"given": "Monika", "family": "Serke", "sequence": "additional", "affiliation": []}, {"given": "Bettina", "family": "Wollschlaeger", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S016950020391659X?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S016950020391659X?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 15]], "date-time": "2019-02-15T18:00:00Z", "timestamp": 1550253600000}, "score": 32.828556, "issued": {"date-parts": [[2003, 8]]}, "references-count": 0, "alternative-id": ["S016950020391659X"], "URL": "http://dx.doi.org/10.1016/s0169-5002(03)91659-x", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T08:03:52Z", "timestamp": 1574409832146}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2010, 1, 1]], "date-time": "2010-01-01T00:00:00Z", "timestamp": 1262304000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2010, 1]]}, "DOI": "10.1016/s0169-5002(10)70022-2", "type": "journal-article", "created": {"date-parts": [[2010, 2, 6]], "date-time": "2010-02-06T09:25:45Z", "timestamp": 1265448345000}, "page": "S7-S8", "source": "Crossref", "is-referenced-by-count": 0, "title": ["A Kent and Medway Cancer Network (KMCN) audit of second-line treatment for non-small cell lung cancer"], "prefix": "10.1016", "volume": "67", "author": [{"given": "C.", "family": "Cafferkey", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Jamal-Hanjani", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Beesley", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Cominos", "sequence": "additional", "affiliation": []}, {"given": "T.", "family": "Sevitt", "sequence": "additional", "affiliation": []}, {"given": "H.", "family": "Taylor", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Burcombe", "sequence": "additional", "affiliation": []}, {"given": "R.", "family": "Shah", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500210700222?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500210700222?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2018, 12, 13]], "date-time": "2018-12-13T11:50:37Z", "timestamp": 1544701837000}, "score": 32.645317, "issued": {"date-parts": [[2010, 1]]}, "references-count": 0, "alternative-id": ["S0169500210700222"], "URL": "http://dx.doi.org/10.1016/s0169-5002(10)70022-2", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:15:45Z", "timestamp": 1575173745547}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 7, 1]], "date-time": "2005-07-01T00:00:00Z", "timestamp": 1120176000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2005, 7]]}, "DOI": "10.1016/s0169-5002(05)80480-5", "type": "journal-article", "created": {"date-parts": [[2005, 9, 7]], "date-time": "2005-09-07T19:17:09Z", "timestamp": 1126120629000}, "page": "S109", "source": "Crossref", "is-referenced-by-count": 0, "title": ["PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results"], "prefix": "10.1016", "volume": "49", "author": [{"given": "J.", "family": "Laskin", "sequence": "first", "affiliation": []}, {"given": "K.", "family": "Chi", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Melosky", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "Sill", "sequence": "additional", "affiliation": []}, {"given": "D.", "family": "Hao", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Canil", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Gleave", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "Murray", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500205804805?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500205804805?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T14:56:38Z", "timestamp": 1548168998000}, "score": 32.319008, "issued": {"date-parts": [[2005, 7]]}, "references-count": 0, "alternative-id": ["S0169500205804805"], "URL": "http://dx.doi.org/10.1016/s0169-5002(05)80480-5", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T05:11:58Z", "timestamp": 1574399518451}, "reference-count": 14, "publisher": "Elsevier BV", "issue": "6", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2009, 11, 1]], "date-time": "2009-11-01T00:00:00Z", "timestamp": 1257033600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Lung Cancer"], "published-print": {"date-parts": [[2009, 11]]}, "DOI": "10.3816/clc.2009.n.080", "type": "journal-article", "created": {"date-parts": [[2009, 12, 18]], "date-time": "2009-12-18T03:47:54Z", "timestamp": 1261108074000}, "page": "426-432", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Second- and Third-line Treatment of Patients With Non\u2013Small-Cell Lung Cancer With Erlotinib in the Community Setting: Retrospective Study of Patient Healthcare Utilization and Symptom Burden"], "prefix": "10.3816", "volume": "10", "author": [{"given": "Edward J.", "family": "Stepanski", "sequence": "first", "affiliation": []}, {"given": "Arthur C.", "family": "Houts", "sequence": "additional", "affiliation": []}, {"given": "Lee S.", "family": "Schwartzberg", "sequence": "additional", "affiliation": []}, {"given": "Mark S.", "family": "Walker", "sequence": "additional", "affiliation": []}, {"given": "Carolina M.", "family": "Reyes", "sequence": "additional", "affiliation": []}, {"given": "Johnetta", "family": "Blakely", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Clinical Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S1525730411701164?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S1525730411701164?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 2, 25]], "date-time": "2019-02-25T06:42:16Z", "timestamp": 1551076936000}, "score": 32.028713, "issued": {"date-parts": [[2009, 11]]}, "references-count": 14, "journal-issue": {"published-print": {"date-parts": [[2009, 11]]}, "issue": "6"}, "alternative-id": ["S1525730411701164"], "URL": "http://dx.doi.org/10.3816/clc.2009.n.080", "ISSN": ["1525-7304"], "issn-type": [{"value": "1525-7304", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 1]], "date-time": "2019-12-01T04:16:01Z", "timestamp": 1575173761409}, "reference-count": 0, "publisher": "Elsevier BV", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2005, 7, 1]], "date-time": "2005-07-01T00:00:00Z", "timestamp": 1120176000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Lung Cancer"], "published-print": {"date-parts": [[2005, 7]]}, "DOI": "10.1016/s0169-5002(05)81035-9", "type": "journal-article", "created": {"date-parts": [[2005, 9, 7]], "date-time": "2005-09-07T19:17:09Z", "timestamp": 1126120629000}, "page": "S260", "source": "Crossref", "is-referenced-by-count": 0, "title": ["P-542 Carboplatin (C) and docetaxel (D) in the second-line treatment of non-small cell lung cancer (NSCLC) patients pretreated with platinum-based regimens. A Phase II trial"], "prefix": "10.1016", "volume": "49", "author": [{"given": "G.", "family": "Numico", "sequence": "first", "affiliation": []}, {"given": "L.", "family": "Buffoni", "sequence": "additional", "affiliation": []}, {"given": "V.", "family": "Dongiovanni", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Schena", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Fissore", "sequence": "additional", "affiliation": []}, {"given": "E.", "family": "Fea", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Occelli", "sequence": "additional", "affiliation": []}, {"given": "I.", "family": "Colantonio", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Merlano", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Bertetto", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Lung Cancer"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0169500205810359?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0169500205810359?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 1, 22]], "date-time": "2019-01-22T14:28:54Z", "timestamp": 1548167334000}, "score": 32.028713, "issued": {"date-parts": [[2005, 7]]}, "references-count": 0, "alternative-id": ["S0169500205810359"], "URL": "http://dx.doi.org/10.1016/s0169-5002(05)81035-9", "ISSN": ["0169-5002"], "issn-type": [{"value": "0169-5002", "type": "print"}], "subject": ["Cancer Research", "Oncology", "Pulmonary and Respiratory Medicine"]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T21:42:03Z", "timestamp": 1574545323835}, "reference-count": 38, "publisher": "Wiley", "content-domain": {"domain": ["wiley.com", "cochranelibrary.com"], "crossmark-restriction": true}, "DOI": "10.1002/14651858.cd011291", "type": "journal-article", "created": {"date-parts": [[2014, 9, 11]], "date-time": "2014-09-11T16:23:22Z", "timestamp": 1410452602000}, "update-policy": "http://dx.doi.org/10.1002/crossmark_policy", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Third-line systemic treatment for non-small cell lung cancer"], "prefix": "10.1002", "author": [{"given": "Stefano C", "family": "Kim", "sequence": "first", "affiliation": [{"name": "University Hospital of Besan\u00e7on; Medical Oncology; 3, Boulevard Alexandre Fleming Besan\u00e7on France 25030"}]}, {"given": "Sophie", "family": "Paget-Bailly", "sequence": "additional", "affiliation": [{"name": "University Hospital of Besan\u00e7on; Methodological and Quality of Life in Oncology Unit; 2 Place Saint Jacques Besan\u00e7on France 25030"}]}, {"given": "Ludovic", "family": "Trinquart", "sequence": "additional", "affiliation": [{"name": "Cochrane France; 1 place du Parvis Notre-Dame Paris France 75004"}]}, {"given": "Fran\u00e7ois", "family": "Calais", "sequence": "additional", "affiliation": [{"name": "University of Franche-Comt\u00e9; University Library; Besan\u00e7on France"}]}, {"given": "Franck", "family": "Bonnetain", "sequence": "additional", "affiliation": [{"name": "University Hospital of Besan\u00e7on; Methodological and Quality of Life Unit in Oncology; 2 Place Saint Jacques Besan\u00e7on France 25030"}]}, {"given": "Virginie", "family": "Westeel", "sequence": "additional", "affiliation": [{"name": "University Hospital of Besan\u00e7on; Thoracic Oncology; 3, Boulevard Alexandre Fleming Besan\u00e7on France 25030"}]}], "member": "311", "published-online": {"date-parts": [[2014, 9, 11]]}, "reference": [{"key": "10.1002/14651858.CD011291-BIB0001|cit1", "doi-asserted-by": "crossref", "first-page": "3825", "DOI": "10.1200/JCO.2010.34.2774", "article-title": "2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer", "volume": "29", "author": "Azzoli", "year": "2011", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0002|cit2", "first-page": "CD002804", "article-title": "Second-line chemotherapy for non-small cell lung cancer", "volume": "2", "author": "Bonfill", "year": "2002", "journal-title": "Cochrane Database of Systematic Reviews"}, {"key": "10.1002/14651858.CD011291-BIB0003|cit3", "doi-asserted-by": "crossref", "first-page": "300", "DOI": "10.1016/S1470-2045(11)70385-0", "article-title": "Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study", "volume": "13", "author": "Ciuleanu", "year": "2012", "journal-title": "Lancet Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0004|cit4", "doi-asserted-by": "crossref", "first-page": "470-84", "DOI": "10.1001/jama.292.4.470", "article-title": "Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis", "volume": "292", "author": "Delbaldo", "year": "2004", "journal-title": "JAMA"}, {"key": "10.1002/14651858.CD011291-BIB0005|cit5", "doi-asserted-by": "crossref", "first-page": "1544-9", "DOI": "10.1097/JTO.0b013e3181bbf223", "article-title": "Third-line chemotherapy in advanced non-small cell lung cancer: Identifying the candidates for routine practice", "volume": "4", "author": "Girard", "year": "2009", "journal-title": "Journal of Thoracic Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0006|cit6", "doi-asserted-by": "crossref", "first-page": "706", "DOI": "10.1097/JTO.0b013e31812f3c1a", "article-title": "The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours", "volume": "2", "author": "Goldstraw", "year": "2007", "journal-title": "Journal of Thoracic Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0007|cit7", "doi-asserted-by": "crossref", "first-page": "1589-97", "DOI": "10.1200/JCO.2004.08.163", "article-title": "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy", "volume": "22", "author": "Hanna", "year": "2004", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0008|cit8", "doi-asserted-by": "crossref", "first-page": "1539", "DOI": "10.1002/sim.1186", "article-title": "Quantifying heterogeneity in a meta-analysis", "volume": "21", "author": "Higgins", "year": "2002", "journal-title": "Statistics in Medicine"}, {"key": "10.1002/14651858.CD011291-BIB0009|cit9", "doi-asserted-by": "crossref", "first-page": "d5928", "DOI": "10.1136/bmj.d5928", "article-title": "The Cochrane Collaboration's tool for assessing risk of bias in randomised trials", "volume": "18", "author": "Higgins", "year": "2011", "journal-title": "BMJ"}, {"key": "10.1002/14651858.CD011291-BIB0010|cit10", "doi-asserted-by": "crossref", "first-page": "1091", "DOI": "10.1503/cmaj.060410", "article-title": "The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey", "volume": "176", "author": "Ioannidis", "year": "2007", "journal-title": "Canadian Medical Association Journal"}, {"key": "10.1002/14651858.CD011291-BIB0011|cit11", "doi-asserted-by": "crossref", "first-page": "878", "DOI": "10.1200/JCO.2011.39.4197", "article-title": "ROS1 rearrangement in lung cancer: A new genomic subset of lung adenocarcinoma", "volume": "30", "author": "J\u00e4nne", "year": "2012", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0012|cit12", "doi-asserted-by": "crossref", "first-page": "1809-18", "DOI": "10.1016/S0140-6736(08)61758-4", "article-title": "Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial", "volume": "372", "author": "Kim", "year": "2008", "journal-title": "Lancet"}, {"key": "10.1002/14651858.CD011291-BIB0013|cit13", "doi-asserted-by": "crossref", "first-page": "1693-1703", "DOI": "10.1056/NEJMoa1006448", "article-title": "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", "volume": "363", "author": "Kwak", "year": "2010", "journal-title": "New England Journal of Medicine"}, {"key": "10.1002/14651858.CD011291-BIB0014|cit14", "doi-asserted-by": "crossref", "first-page": "2380-8", "DOI": "10.1056/NEJMoa0909530", "article-title": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", "volume": "362", "author": "Maemondo", "year": "2010", "journal-title": "New England Journal of Medicine"}, {"key": "10.1002/14651858.CD011291-BIB0015|cit15", "doi-asserted-by": "crossref", "first-page": "4244-52", "DOI": "10.1200/JCO.2007.15.0185", "article-title": "Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer", "volume": "26", "author": "Maruyama", "year": "2008", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0016|cit16", "doi-asserted-by": "crossref", "first-page": "55-61", "DOI": "10.1016/S0169-5002(02)00308-2", "article-title": "A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer", "volume": "39", "author": "Massarelli", "year": "2003", "journal-title": "Lung Cancer"}, {"key": "10.1002/14651858.CD011291-BIB0017|cit17", "doi-asserted-by": "crossref", "first-page": "121-8", "DOI": "10.1016/S1470-2045(09)70364-X", "article-title": "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial", "volume": "11", "author": "Mitsudomi", "year": "2010", "journal-title": "Lancet Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0018|cit18", "doi-asserted-by": "crossref", "first-page": "947-57", "DOI": "10.1056/NEJMoa0810699", "article-title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", "volume": "361", "author": "Mok", "year": "2009", "journal-title": "New England Journal of Medicine"}, {"issue": "6", "key": "10.1002/14651858.CD011291-BIB0019|cit19", "doi-asserted-by": "crossref", "first-page": "1710", "DOI": "10.1378/chest.111.6.1710", "article-title": "Revisions in the International System for Staging Lung Cancer", "volume": "111", "author": "Mountain", "year": "1997", "journal-title": "Chest"}, {"key": "10.1002/14651858.CD011291-BIB0020|cit20", "doi-asserted-by": "crossref", "first-page": "1095-9", "DOI": "10.1634/theoncologist.11-10-1095", "article-title": "Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer", "volume": "11", "author": "Murillo", "year": "2006", "journal-title": "The Oncologist"}, {"key": "10.1002/14651858.CD011291-BIB0021|cit21", "unstructured": "www.nccn.org/professionals/physician_gls/f_guidelines.asp (accessed 19March 2014)"}, {"key": "10.1002/14651858.CD011291-BIB0022|cit22", "doi-asserted-by": "crossref", "first-page": "4617-25", "DOI": "10.1200/JCO.2008.17.7162", "article-title": "Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials", "volume": "26", "author": "NSCLC Meta-Analyses Collaborative Group", "year": "2008", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0023|cit23", "author": "10.1002/14651858.CD002139 Non-Small Cell Lung Cancer Collaborative Group", "issue": "2", "year": "2000", "article-title": "Chemotherapy can improve survival rates for non-small cell lung cancer", "journal-title": "Cochrane Database of Systematic Reviews", "DOI": "10.1002/14651858.CD002139", "doi-asserted-by": "publisher"}, {"key": "10.1002/14651858.CD011291-BIB0024|cit24", "first-page": "1447", "article-title": "Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints", "volume": "82", "author": "Parmar", "year": "1998", "journal-title": "Statistics in Medicine"}, {"key": "10.1002/14651858.CD011291-BIB0025|cit25", "first-page": "vii56", "article-title": "Metastatic Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up", "volume": "23 Suppl 7", "author": "Peters", "year": "2012", "journal-title": "Annals of Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0026|cit26", "unstructured": "The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"}, {"key": "10.1002/14651858.CD011291-BIB0027|cit27", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1016/S1470-2045(11)70393-X", "article-title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial", "volume": "13", "author": "Rosell", "year": "2012", "journal-title": "Lancet Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0028|cit28", "doi-asserted-by": "crossref", "first-page": "746", "DOI": "10.1002/sim.2971", "article-title": "Arcsine test for publication bias in meta-analyses with binary outcomes", "volume": "27", "author": "R\u00fccker", "year": "2008", "journal-title": "Statistics in Medicine"}, {"issue": "1", "key": "10.1002/14651858.CD011291-BIB0029|cit29", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1093/biostatistics/kxq046", "article-title": "Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis", "volume": "12", "author": "R\u00fccker", "year": "2011", "journal-title": "Biostatistics (Oxford, England)"}, {"key": "10.1002/14651858.CD011291-BIB0030|cit30", "unstructured": "http://seer.cancer.gov/csr/1975_2004/results_merged/sect_15_lung_bronchus.pdf (17 December 2012) http://seer.cancer.gov/statfacts/html/lungb.html"}, {"key": "10.1002/14651858.CD011291-BIB0031|cit31", "doi-asserted-by": "crossref", "first-page": "1483-8", "DOI": "10.1093/annonc/mdp031", "article-title": "Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel", "volume": "20", "author": "Sekine", "year": "2009", "journal-title": "Annals of Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0032|cit32", "doi-asserted-by": "crossref", "first-page": "2095", "DOI": "10.1200/JCO.2000.18.10.2095", "article-title": "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy", "volume": "18", "author": "Shepherd", "year": "2000", "journal-title": "Journal of Clinical Oncology"}, {"key": "10.1002/14651858.CD011291-BIB0033|cit33", "doi-asserted-by": "crossref", "first-page": "123-32", "DOI": "10.1056/NEJMoa050753", "article-title": "Erlotinib in previously treated non-small-cell lung cancer", "volume": "353", "author": "Shepherd", "year": "2005", "journal-title": "New England Journal of Medicine"}, {"key": "10.1002/14651858.CD011291-BIB0034|cit34", "first-page": "10-29", "article-title": "Cancer statistics 2012", "volume": "62", "author": "Siegel", "year": "2012", "journal-title": "CA: A Cancer Journal for Clinicians"}, {"key": "10.1002/14651858.CD011291-BIB0035|cit35", "doi-asserted-by": "crossref", "first-page": "771-5", "DOI": "10.1136/bmj.317.7161.771", "article-title": "Preferences for chemotherapy in patients with advanced non-small cell lung cancer: Descriptive study based on scripted interviews", "volume": "317", "author": "Silvestri", "year": "1998", "journal-title": "BMJ"}, {"issue": "3", "key": "10.1002/14651858.CD011291-BIB0036|cit36", "doi-asserted-by": "crossref", "first-page": "205", "DOI": "10.1093/jnci/92.3.205", "article-title": "New guideline to evaluate the response to treatment in solid tumors", "volume": "92", "author": "Therasse", "year": "2000", "journal-title": "Journal of the National Cancer institute"}, {"key": "10.1002/14651858.CD011291-BIB0037|cit37", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1186/1745-6215-8-16", "article-title": "Practical methods for incorporating summary time-to-event data into meta-analysis", "volume": "8", "author": "Tierney", "year": "2007", "journal-title": "Trials"}, {"key": "10.1002/14651858.CD011291-BIB0038|cit38", "doi-asserted-by": "crossref", "first-page": "735-42", "DOI": "10.1016/S1470-2045(11)70184-X", "article-title": "Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study", "volume": "12", "author": "Zhou", "year": "2011", "journal-title": "Lancet Oncology"}], "container-title": ["Cochrane Database of Systematic Reviews"], "language": "en", "link": [{"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/14651858.CD011291", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 8, 5]], "date-time": "2018-08-05T21:43:56Z", "timestamp": 1533505436000}, "score": 31.855194, "editor": [{"name": "Cochrane Lung Cancer Group", "sequence": "additional", "affiliation": []}], "issued": {"date-parts": [[2014, 9, 11]]}, "references-count": 38, "URL": "http://dx.doi.org/10.1002/14651858.cd011291", "relation": {"cites": []}, "ISSN": ["1465-1858"], "issn-type": [{"value": "1465-1858", "type": "electronic"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}